Brief: Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400

Ocugen

13/01/2025 11:53

Jan 13 (Reuters) - Ocugen Inc  OCGN.O :
    * OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS
MULTIPLE
MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL
MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA
    * OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY
    * PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026

Source text:  ID:nGNX9GR3Wq 
Further company coverage:  OCGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))